Urotensin II is a New Chemotactic Factor for UT Receptor-Expressing Monocytes1

Urotensin II (U-II), a vasoactive cyclic neuropeptide which activates the G protein-coupled receptor UT receptor, exerts various cardiovascular effects and may play a role in the pathophysiology of atherosclerosis. In this study, we report that the UT receptor is expressed and functional on human PBMC and rat splenocytes. PBMC surface expression of the UT receptor was mainly found in monocytes and NK cells, also in a minority of B cells, but not in T cells. Stimulation of monocytes with LPS increased UT receptor mRNA and protein expression. Cloning and functional characterization of the human UT receptor gene promoter revealed the presence of NF-κB-binding sites involved in the stimulation of UT receptor gene expression by LPS. Activation of the UT receptor by U-II induced chemotaxis with maximal activity at 10 and 100 nM. This U-II effect was restricted to monocytes. Analysis of the signaling pathway involved indicated that U-II-mediated chemotaxis was related to RhoA and Rho kinase activation and actin cytoskeleton reorganization. The present results thus identify U-II as a chemoattractant for UT receptor-expressing monocytes and indicate a pivotal role of the RhoA-Rho kinase signaling cascade in the chemotaxis induced by U-II.

[1]  S. Douglas,et al.  Expression of urotensin-II in human coronary atherosclerosis , 2005, Peptides.

[2]  J. Hamilton,et al.  Regulation of Toll‐like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis‐related antigens , 2005, Clinical and experimental immunology.

[3]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[4]  Hassan Oulyadi,et al.  Structure–activity relationships and structural conformation of a novel urotensin II-related peptide , 2004, Peptides.

[5]  A. Davenport,et al.  Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries , 2004, Peptides.

[6]  S. Douglas,et al.  Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. , 2004, Atherosclerosis.

[7]  K. Moore,et al.  Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways , 2004, Nature Medicine.

[8]  John G. Collard,et al.  RhoA activation promotes transendothelial migration of monocytes via ROCK , 2004, Journal of leukocyte biology.

[9]  Miguel Vicente-Manzanares,et al.  Role of the cytoskeleton during leukocyte responses , 2004, Nature Reviews Immunology.

[10]  B. Charbonnel,et al.  B cell-adherent splenocytes precede the onset of diabetes in low-dose streptozotocin-treated mice , 2004, Diabetologia.

[11]  J. Siegfried,et al.  Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells , 2003, Journal of Neuroimmunology.

[12]  A. Tedgui,et al.  Rho-Associated Protein Kinase Contributes to Early Atherosclerotic Lesion Formation in Mice , 2003, Circulation research.

[13]  F. Bloom,et al.  Neuropeptides: opportunities for drug discovery , 2003, The Lancet Neurology.

[14]  Marianne Frieri,et al.  Neuroimmunology and inflammation: implications for therapy of allergic and autoimmune diseases. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  David G. Behm,et al.  Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice , 2003, British journal of pharmacology.

[16]  J. Galmiche,et al.  Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. , 2003, Gastroenterology.

[17]  D. Kimes,et al.  Environmental allergens and asthma in urban elementary schools. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  A. Hall,et al.  Rho GTPases in cell biology , 2002, Nature.

[19]  A. Davenport,et al.  Is urotensin‐II the new endothelin? , 2002, British journal of pharmacology.

[20]  F. Balkwill,et al.  Endothelin‐2 is a macrophage chemoattractant: implications for macrophage distribution in tumors , 2002, European journal of immunology.

[21]  K. Schäkel,et al.  The CD16+ (FcγRIII+) Subset of Human Monocytes Preferentially Becomes Migratory Dendritic Cells in a Model Tissue Setting , 2002, The Journal of experimental medicine.

[22]  J. Pernow,et al.  Urotensin II evokes potent vasoconstriction in humans in vivo , 2002, British journal of pharmacology.

[23]  F. Sánchez‐Madrid,et al.  A Role for the Rho-p160 Rho Coiled-Coil Kinase Axis in the Chemokine Stromal Cell-Derived Factor-1α-Induced Lymphocyte Actomyosin and Microtubular Organization and Chemotaxis1 , 2002, The Journal of Immunology.

[24]  A. Kavelaars,et al.  Role and modulation of G protein-coupled receptor signaling in inflammatory processes. , 2002, Critical reviews in immunology.

[25]  E. Kostenis,et al.  Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  M. Shichiri,et al.  Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues , 2001, Journal of hypertension.

[27]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[28]  A. Ridley.  Rho GTPases and cell migration. , 2001, Journal of cell science.

[29]  T. Katagiri,et al.  Synergistic Effect of Urotensin II With Mildly Oxidized LDL on DNA Synthesis in Vascular Smooth Muscle Cells , 2001, Circulation.

[30]  K. Takeda,et al.  Rho-Kinase Mediates Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression in Rat Vascular Smooth Muscle Cells , 2001, Hypertension.

[31]  J. Bertoglio,et al.  Human Urotensin II–Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase , 2001, Circulation research.

[32]  C. Serhan,et al.  Cutting Edge: Nociceptin Stimulates Neutrophil Chemotaxis and Recruitment: Inhibition by Aspirin-Triggered-15-Epi-Lipoxin A41 , 2001, The Journal of Immunology.

[33]  M. Delgado,et al.  Cutting Edge: Is Vasoactive Intestinal Peptide a Type 2 Cytokine? , 2001, The Journal of Immunology.

[34]  H. Tilg,et al.  Cutting Edge: Peripheral Neuropeptides Attract Immature and Arrest Mature Blood-Derived Dendritic Cells1 , 2001, The Journal of Immunology.

[35]  K. Kaibuchi,et al.  Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. , 2001, Trends in pharmacological sciences.

[36]  H. Sarau,et al.  Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.

[37]  A. Davenport,et al.  Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1 , 2000, British journal of pharmacology.

[38]  S. Lohmann,et al.  Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth Muscle* , 2000, The Journal of Biological Chemistry.

[39]  S. Douglas,et al.  Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat , 2000, British journal of pharmacology.

[40]  T. Werner,et al.  Highly specific localization of promoter regions in large genomic sequences by PromoterInspector: a novel context analysis approach. , 2000, Journal of molecular biology.

[41]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[42]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[43]  W. Kiosses,et al.  Regulation of the small GTP‐binding protein Rho by cell adhesion and the cytoskeleton , 1999, The EMBO journal.

[44]  H. Vaudry,et al.  Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Schölmerich,et al.  Dialogue between the CNS and the immune system in lymphoid organs. , 1998, Immunology today.

[46]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[47]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[48]  Daniel Zicha,et al.  A Role for Cdc42 in Macrophage Chemotaxis , 1998, The Journal of cell biology.

[49]  G. Schmitz,et al.  Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[50]  H. Ziegler-Heitbrock,et al.  Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. , 1996, Immunology today.

[51]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[52]  T. Werner,et al.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. , 1995, Nucleic acids research.

[53]  P. Murphy.  The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.

[54]  D. Carson,et al.  Effect of neuropeptides on production of inflammatory cytokines by human monocytes. , 1989, Science.